Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23248374 | 0.92 | ALDH1A1 (0.42) | L3MBTL1ALDH1A1HSD17B10KDM4EHPGD | |
| SCHEMBL9261071 | 0.89 | ALDH1A1 (0.54) | ALDH1A1HSD17B10KDM4EHPGDALOX15 | |
| SCHEMBL20568530 | 0.88 | ALDH1A1 (0.43) | L3MBTL1ALDH1A1HSD17B10KDM4ETSHR | |
| SCHEMBL31434014 | 0.84 | MAPT (0.62) | L3MBTL1ALDH1A1KDM4EMAPTPOLB | |
| SCHEMBL23248450 | 0.81 | ALDH1A1 (0.51) | ALDH1A1HSD17B10KDM4EHPGDALOX15 | |
| SCHEMBL11076507 | 0.81 | L3MBTL1 (0.53) | L3MBTL1ALDH1A1KDM4EALOX15TSHR | |
| SCHEMBL4847106 | 0.79 | ALDH1A1 (0.48) | L3MBTL1ALDH1A1HSD17B10KDM4EHPGD | |
| SCHEMBL11075024 | 0.78 | L3MBTL1 (0.49) | L3MBTL1ALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL11313274 | 0.78 | ALDH1A1 (0.60) | L3MBTL1ALDH1A1HSD17B10KDM4EHPGD | |
| SCHEMBL9284157 | 0.77 | ALDH1A1 (0.56) | L3MBTL1ALDH1A1HSD17B10KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729127-A2 | BCL6 INHIBITORS | Cancer Research Technology Limited (GB) | 2026-04-22 | — | — | EP | disclosed |
| US-20260042776-A1 | BCL6 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-12486285-B2 | BCL6 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-12-02 | — | — | US | disclosed |
| CN-112334475-B | BCL6 inhibitors | 癌症研究技术有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20240217987-A1 | INHIBITOR COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-04 | — | — | US | disclosed |
| US-20230287003-A1 | BCL6 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-14 | — | — | US | disclosed |
| US-20230287003-A1 | BCL6 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-14 | — | — | US | disclosed |
| US-20230287003-A1 | BCL6 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-14 | — | — | US | disclosed |
| EP-4201939-A1 | BCL6 INHIBITORS | Cancer Research Technology Limited (GB) | 2023-06-28 | — | — | EP | disclosed |
| EP-3774817-B1 | BCL6 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2022-12-07 | — | — | EP | disclosed |
| EP-3774817-B1 | BCL6 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2022-12-07 | — | — | EP | disclosed |
| US-11512095-B2 | BCL6 inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-11-29 | — | — | US | disclosed |
| US-20210163497-A1 | BCL6 INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-06-03 | — | — | US | disclosed |
| US-20210163497-A1 | BCL6 INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-06-03 | — | — | US | disclosed |
| EP-3774817-A1 | BCL6 INHIBITORS | Cancer Research Technology Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| CN-112334475-A | BCL6 inhibitor | 癌症研究技术有限公司 | 2021-02-05 | — | — | CN | disclosed |
| WO-2019197842-A1 | BCL6 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019197842-A1 | BCL6 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163497-A1 | BCL6 INHIBITORS | BCL6, BCL6B, BCL3 | L3MBTL1 536/4885ALDH1A1 2602/4885HSD17B10 1125/4885 |
| US-20230287003-A1 | BCL6 INHIBITORS | BCL6, BCL6B, BCL3 | L3MBTL1 536/4885ALDH1A1 2602/4885HSD17B10 1125/4885 |
| US-12486285-B2 | BCL6 inhibitors | BCL6, BCL6B, BCL3 | L3MBTL1 536/4885ALDH1A1 2602/4885HSD17B10 1125/4885 |
| US-11512095-B2 | BCL6 inhibitors | BCL6, BCL6B, BCL3 | L3MBTL1 536/4885ALDH1A1 2602/4885HSD17B10 1125/4885 |
| US-20240217987-A1 | INHIBITOR COMPOUNDS | BCL6, BCL6B, BCL3 | L3MBTL1 653/4885ALDH1A1 2960/4885HSD17B10 1571/4885 |
| US-20260042776-A1 | BCL6 INHIBITORS | BCL6, BCL6B, BCL9 | L3MBTL1 1893/4885ALDH1A1 3510/4885HSD17B10 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.